Skip to content

Frontiers in Pharmacology

ISSN 1663-9812

168 papers in the library · 6,102 citations · publishing 2012-2026

Papers

Sort Most recent Most cited

MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor

Frontiers in Pharmacology July 11, 2017 Drew J. Puxty, Johannes G. Ramaekers, Rafael de la Torre et al. 33 citations

Previous research has shown that a single dose of MDMA induce a dissociative state, by elevating feelings of depersonalization and derealization. Typically, it is assumed that action on the 5-HT2A receptor is the mechanism underlying these psychedelic experiences. In addition, other studies have shown associations between dissociative states and biological parameters (heart rate, cortisol),...

DOI: 10.3389/fphar.2017.00455 (opens in new tab) MDMA Dissociative Pharmacology Hallucinogen +1

A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects

Frontiers in Pharmacology June 28, 2017 Patrick C. Dolder, Edna Grünblatt, Felix Müller et al. 12 citations

Rationale Renewed interest has been seen in the use of lysergic acid diethylamide (LSD) in psychiatric research and practice. The repeated use of LSD leads to tolerance that is believed to result from serotonin (5-HT) 5-HT2A receptor downregulation. In rats, daily LSD administration for 4 days decreased frontal cortex 5-HT2A receptor binding. Additionally, a single dose of LSD acutely increased...

Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research

Frontiers in Pharmacology June 21, 2017 Rafael Naime Ruggiero, Matheus Teixeira Rossignoli, Jana Batista de Ross et al. 37 citations

Much of our knowledge of the endocannabinoid system in schizophrenia comes from behavioral measures in rodents, like prepulse inhibition of the acoustic startle and open-field locomotion, which are commonly used along with neurochemical approaches or drug challenge designs. Such methods continue to map fundamental mechanisms of sensorimotor gating, hyperlocomotion, social interaction, and...

DOI: 10.3389/fphar.2017.00399 (opens in new tab) Cannabidiol Cannabis Schizophrenia object-oriented programming Prepulse inhibition +7

Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders

Frontiers in Pharmacology May 23, 2017 Alline Cristina Campos, Manoela V. Fogaça, Franciele Franco Scarante et al. 176 citations

Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces...

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life

Frontiers in Pharmacology May 11, 2017 Antônio Waldo Zuardi, Natália Pegoraro Rodrigues, Angélica L. Silva et al. 292 citations

The purpose of this study was to investigate whether the anxiolytic effect of cannabidiol (CBD) in humans follows the same pattern of an inverted U-shaped dose-effect curve observed in many animal studies. Sixty healthy subjects of both sexes aged between 18 and 35 years were randomly assigned to five groups that received placebo, clonazepam (1 mg), and CBD (100, 300, and 900 mg). The subjects...

Cannabis in Chinese Medicine: Are Some Traditional Indications Referenced in Ancient Literature Related to Cannabinoids?

Frontiers in Pharmacology March 10, 2017 E. Brand, Zhong-Zhen Zhao

Cannabis sativa L. (Cannabaceae) has a long history of utilization as a fiber and seed crop in China, and its achenes (“seeds”) as well as other plant parts have been recorded in Chinese medical texts for nearly 2000 years. While the primary applications of cannabis in Chinese medicine center around the use of the achenes, ancient indications for the female inflorescence, and other plant parts...

Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans

Frontiers in Pharmacology September 27, 2016 Sara de la Salle, Joëlle Choueiry, D. Shah et al.

N-methyl-D-aspartate (NMDA) receptor antagonists administered to healthy humans results in schizophrenia-like symptoms, which preclinical research suggests are due to glutamatergically altered brain oscillations. Here, we examined resting-state electroencephalographic activity in 21 healthy volunteers assessed in a placebo-controlled, double-blind, randomized study involving administration of...

The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization.

Frontiers in Pharmacology March 2, 2016 Ede Frecska, Petra Bokor, Michael Winkelman 237 citations

Ayahuasca is an Amazonian psychoactive brew of two main components. Its active agents are β-carboline and tryptamine derivatives. As a sacrament, ayahuasca is still a central element of many healing ceremonies in the Amazon Basin and its ritual consumption has become common among the mestizo populations of South America. Ayahuasca use amongst the indigenous people of the Amazon is a form of...

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience.

Frontiers in Pharmacology 2016 Andrew R. Gallimore, Rick J. Strassman 51 citations

The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the most extraordinary of any naturally-occurring psychedelic substance. Users consistently report the complete replacement of normal subjective experience with a novel "alternate universe," often densely populated with a variety of strange objects and other highly complex visual content, including what appear to be...

The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization

Frontiers in Pharmacology 2016 Petra Bokor, Ede Frecska, Michael Winkelman

Ayahuasca is an Amazonian psychoactive brew of two main components. Its active agents are β-carboline and tryptamine derivatives. As a sacrament, ayahuasca is still a central element of many healing ceremonies in the Amazon Basin and its ritual consumption has become common among the mestizo populations of South America. Ayahuasca use amongst the indigenous people of the Amazon is a form of...

DOI: 10.3389/fphar.2016.00035/full (opens in new tab) Full text (opens in new tab) Psychedelics Traditional medicine Mental health Ethnobotany

Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders

Frontiers in Pharmacology September 8, 2015 Mary Jeanne Kreek, Eduardo R Butelman 77 citations

Salvinorin A is a potent hallucinogen, isolated from the ethnomedical plant Salvia divinorum. Salvinorin A is a selective high efficacy kappa-opioid receptor (KOPr) agonist, and thus implicates the KOPr system and its endogenous agonist ligands (the dynorphins) in higher functions, including cognition and perceptual effects. Salvinorin A is the only selective KOPr ligand to be widely available...

DOI: 10.3389/fphar.2015.00190 (opens in new tab) Hallucinogen Κ-opioid receptor Pharmacology Dynorphin +1

Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders.

Frontiers in Pharmacology 2015 Eduardo R Butelman, Mary Jeanne Kreek 3 citations correction

In the original review, we placed an incorrect citation in a sentence. The correct sentence and citation are as follows: "Also, salvinorin A can act as a “punisher” to self-administration of cocaine or a short-acting MOPr agonist in primates (when given contingently; Freeman et al., 2014).” The authors apologize for the mistake. This error does not change the scientific conclusions of the...

Inducible Nitric Oxide Inhibitors Block NMDA Antagonist-Stimulated Motoric Behaviors and Medial Prefrontal Cortical Glutamate Efflux.

Frontiers in Pharmacology 2015 Hadley C Bergstrom, Altaf S Darvesh, S P Berger

Nitric oxide (NO) plays a critical role in the motoric and glutamate releasing action of N-methyl-D-aspartate (NMDA)-antagonist stimulants. Earlier studies utilized neuronal nitric oxide synthase inhibitors (nNOS) for studying the neurobehavioral effects of non-competitive NMDA-antagonist stimulants such as dizocilpine (MK-801) and phencyclidine (PCP). This study explores the role of the...

Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain

Frontiers in Pharmacology 2014 Raquel Levin, Fernanda Fiel Peres, Valéria de Almeida et al. 73 citations

Clinical and neurobiological findings suggest that the cannabinoids and the endocannabinoid system may be implicated in the pathophysiology and treatment of schizophrenia. We described that the spontaneously hypertensive rats (SHR) strain presents a schizophrenia behavioral phenotype that is specifically attenuated by antipsychotic drugs, and potentiated by proschizophrenia manipulations. Based...

Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms.

Frontiers in Pharmacology 2014 Petra Amchova, Jana Kučerová, Valentina Giugliano et al.

Depression has been associated with drug consumption, including heavy or problematic cannabis use. According to an animal model of depression and substance use disorder comorbidity, we combined the olfactory bulbectomy (OBX) model of depression with intravenous drug self-administration procedure to verify whether depressive-like rats displayed altered voluntary intake of the CB1 receptor...

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

Frontiers in Pharmacology October 14, 2013 Caroline A Browne, Irwin Lucki

Newer antidepressants are needed for the many individuals with major depressive disorder (MDD) that do not respond adequately to treatment and because of a delay of weeks before the emergence of therapeutic effects. Recent evidence from clinical trials shows that the NMDA antagonist ketamine is a revolutionary novel antidepressant because it acts rapidly and is effective for treatment-resistant...

Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses

Frontiers in Pharmacology 2013 Wendy K. Adams, Adam L. Halberstadt, Maarten Van den Buuse 11 citations

Antagonism of N-methyl-D-aspartate (NMDA) receptors by phencyclidine (PCP) is thought to underlie its ability to induce a schizophrenia-like syndrome in humans, yet evidence indicates it has a broader pharmacological profile. Our previous lesion studies highlighted a role for serotonergic projections from the median, but not dorsal, raphe nucleus in mediating the hyperlocomotor effects of PCP,...

Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia.

Frontiers in Pharmacology 2012 Adriana Caballero, Kuei Y Tseng

The cannabinoid receptor 1 (CB1R) is the G-protein coupled receptor responsible for the majority of the endocannabinoid signaling in the human brain. It is widely distributed in the limbic system, basal ganglia, and cerebellum, which are areas responsible for cognition, memory, and motor control. Because of this widespread distribution, it is not surprising that drugs that activate CB1R have...

DOI: 10.3389/fphar.2012.00101 (opens in new tab) Full text (opens in new tab) Adolescence Cannabinoids Prefrontal cortex Schizophrenia